Fabtech Technologies Ltd
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company.[1]
- Market Cap ₹ 696 Cr.
- Current Price ₹ 157
- High / Low ₹ 263 / 126
- Stock P/E 18.8
- Book Value ₹ 94.4
- Dividend Yield 0.00 %
- ROCE 13.6 %
- ROE 12.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.8% CAGR over last 5 years
Cons
- Earnings include an other income of Rs.22.7 Cr.
- Company has high debtors of 182 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 133 | 121 | 257 | 194 | 226 | 327 | 411 | |
| 119 | 110 | 225 | 169 | 191 | 288 | 376 | |
| Operating Profit | 14 | 11 | 32 | 25 | 35 | 39 | 35 |
| OPM % | 11% | 9% | 12% | 13% | 15% | 12% | 9% |
| 5 | 2 | 4 | 10 | 6 | 27 | 23 | |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 | 4 |
| Depreciation | 0 | 0 | 2 | 2 | 2 | 3 | 5 |
| Profit before tax | 16 | 11 | 31 | 28 | 36 | 60 | 48 |
| Tax % | 27% | 29% | 25% | 22% | 24% | 23% | 21% |
| 12 | 8 | 23 | 22 | 27 | 46 | 38 | |
| EPS in Rs | 12,390.00 | 8,040.00 | 84.28 | 78.00 | 92.44 | 14.34 | 8.63 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 28% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 19% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 17% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 3 | 3 | 3 | 32 | 44 |
| Reserves | 38 | 46 | 65 | 86 | 129 | 141 | 375 |
| 1 | 9 | 21 | 35 | 13 | 84 | 70 | |
| 84 | 70 | 83 | 89 | 125 | 170 | 164 | |
| Total Liabilities | 123 | 126 | 172 | 214 | 269 | 427 | 654 |
| 2 | 2 | 5 | 4 | 22 | 94 | 78 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 12 | 7 | 17 | 20 | 21 | 15 | 26 |
| 109 | 116 | 150 | 190 | 226 | 318 | 550 | |
| Total Assets | 123 | 126 | 172 | 214 | 269 | 427 | 654 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 64 | -9 | -3 | -14 | 60 | -36 | 0 | |
| -28 | 4 | -9 | 2 | -30 | -20 | -112 | |
| -23 | 6 | 8 | 12 | -12 | 36 | 190 | |
| Net Cash Flow | 13 | 1 | -4 | -0 | 18 | -20 | 78 |
| Free Cash Flow | 64 | -9 | -4 | -14 | 59 | -61 | 5 |
| CFO/OP | 417% | -65% | 4% | -15% | 196% | -68% | 36% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 120 | 187 | 156 | 168 | 182 |
| Inventory Days | 22 | 39 | 17 | 69 | 88 | 119 | 32 |
| Days Payable | 82 | 150 | 136 | 215 | 195 | 198 | 159 |
| Cash Conversion Cycle | 51 | 25 | 1 | 41 | 49 | 89 | 55 |
| Working Capital Days | -19 | 15 | 30 | 65 | 63 | 53 | 90 |
| ROCE % | 26% | 48% | 31% | 28% | 22% | 14% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Book to Bill Ratio Ratio |
|
||
| In-house Manufacturing Share of Project Supplies % |
|||
| New Order Intake INR Lakhs |
|||
| Number of Projects Delivered Globally Count |
|||
| Proposal to Order Conversion Ratio % |
|||
| Total Unexecuted Order Book INR Lakhs |
|||
| Number of Countries of Presence Count |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
7 May - CRISIL report for quarter ended March 31, 2026 shows IPO proceeds utilization, no deviations, and working capital delay.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Apr - Please find attached transcript of Earnings Conference Call
- Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Apr
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 Apr - Recording of earnings call for Q4 and FY2026 audited results shared on April 28, 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - Fabtech Technologies announced Q4 and FY26 audited results: ₹431.33 crore income, ₹38.36 crore PAT.
Concalls
-
Apr 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
Fabtech provides end-to-end turnkey pharma plant solutions covering design, engineering, procurement, installation, and regulatory validation, while also offering standalone execution services like equipment supply and installation for clients with their own designs.